Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Daiichi Sankyo
Medtronic
Merck
Chubb
Cipla
Argus Health
McKinsey

Generated: May 28, 2018

DrugPatentWatch Database Preview

Granisetron - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for granisetron and what is the scope of granisetron patent protection?

Granisetron
is the generic ingredient in six branded drugs marketed by Kyowa Kirin, Heron Theraps Inc, Akorn Inc, Aurobindo Pharma Ltd, Baxter Hlthcare Corp, Bionpharma Inc, Cipla Ltd, Fresenius Kabi Usa, Hikma Farmaceutica, Luitpold, Mylan Asi, Mylan Labs Ltd, Sandoz Inc, Teva Pharms Usa, West-ward Pharms Int, Wockhardt Usa, Roche, Pediatrx, Apotex Inc, Barr, Chartwell Molecular, Dr Reddys Labs Ltd, Epic Pharma Llc, Mylan, Natco Pharma, Orchid Hlthcare, Taro Pharm, and Teva Pharms, and is included in fifty NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Granisetron has fifty-six patent family members in thirty-two countries.

There are twenty-six drug master file entries for granisetron. Three suppliers are listed for this compound.
Pharmacology for granisetron
Medical Subject Heading (MeSH) Categories for granisetron
Synonyms for granisetron
1-Methyl-1H-indazole-3-carboxylic acid (9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-amide
1-METHYL-N-((1R,3R,5S)-9-METHYL-9-AZABICYCLO[3.3.1]NONAN-3-YL)-1H-INDAZOLE-3-CARBOXAMIDE
1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-indazole-3-carboxamide
1-Methyl-N-(9-methyl-endo-9-azabicyclo(3.3.1)non-3-yl)-1H-indazole-3-carboxamide
1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide
1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide
1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-7-yl]indazole-3-carboxamide
1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide
107007-99-8 (mono-hydrochloride)
109889-09-0
121061-98-1
124998-65-8
1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-, endo-
1H-INDAZOLE-3-CARBOXAMIDE, 1-METHYL-N-[(3-ENDO)-9-METHYL-9-AZABICYCLO[3.3.1]NON-3-YL]-
3702AH
889g090
A802101
AB00918713-07
AB07494
AC-8910
AC1NR4P1
AKOS025402424
AN-7538
APF 530
APF530
API0005490
BDBM50443668
BDBM50449636
BIDD:GT0272
BRL 43694
BRL 43964
BRL-43694
C07023
CCG-221158
CHEBI:5537
CHEBI:94501
CHEMBL1290003
D04370
D0J5KF
DB00889
DL-166
DTXSID0023111
ENDO-GRANISETRON
FT-0626805
GRANESETRON
Granisetron (JAN/USAN/INN)
Granisetron (USAN/INN)
Granisetron [USAN:INN:BAN:JAN]
Granisetron Monohydrochloride
Granisetronum
GTPL2300
HMS2089P14
Kevatril
Kevatril|||1-Methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide,
Kytril (TN)
Q-101870
Sancuso
Sancuso (TN)
SCHEMBL34178
SCHEMBL4890
SCHEMBL4891
Sustol
UNII-WZG3J2MCOL
VA11035
W-5139
WZG3J2MCOL
ZINC100018852
ZINC100018854
ZINC347

US Patents and Regulatory Information for granisetron

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd GRANISETRON HYDROCHLORIDE granisetron hydrochloride INJECTABLE;INJECTION 204238-001 Jul 6, 2016 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Baxter Hlthcare Corp GRANISETRON HYDROCHLORIDE granisetron hydrochloride INJECTABLE;INJECTION 078198-002 Jun 30, 2008 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bionpharma Inc GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE granisetron hydrochloride INJECTABLE;INJECTION 078863-002 Jun 30, 2008 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sandoz Inc GRANISETRON HYDROCHLORIDE granisetron hydrochloride INJECTABLE;INJECTION 078835-001 Jun 30, 2008 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for granisetron

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,861,068 Pharmaceutical compositions using semi-solid delivery vehicle ➤ Sign Up
8,252,306 Process for preparing a semi-solid delivery vehicle comprising granisetron ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Dow
Cantor Fitzgerald
Queensland Health
Johnson and Johnson
Accenture
Daiichi Sankyo
Moodys
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.